(Illustration) The vaccine trial looked at 16 patients. Photo: Shutterstock.
Biotechnology experts announced good results of the phase 1 clinical trial made to a breast cancer vaccine, developed by the company Anixa Biosciencesin collaboration with the Cleveland Clinic and with the financing of United States Department of Defenselast December 6.
“The data of our phase 1 trial To date they have exceeded our expectations and we are pleased with our progress. This vaccine is designed to direct the immune system to destroy cancer cells TNBC through a mechanism that has never been used before for the development of cancer vaccines“said Amit Kumar, president and CEO of Anixa Biosciences.
What were the results of the breast cancer vaccine trial?
The trial revealed that all 16 patients at high risk for operable triple negative breast cancer (TNBC) who participated in the study developed responses in the T cells, that met the rigorous definition of immune response specified in the protocol, when administered three vaccines, once every two weeks.
Additionally, 12 of the 16 women who participated in the clinical trial had responses of ELISA antibodies by receiving at least two doses 2 of the breast cancer vaccine.
This helped the experts determine that, a breast cancer vaccine dose, composed of 10 mcg of α-lactalbumin and 10 mcg of zymosan, was a usable immunological dose, as well as the maximum tolerated dose. And no significant side effects were observed, other than irritation at the injection sites.
No myalgia, flu-like symptoms, or aberrant laboratory values were observed, he indicated. Anixa Biosciences in a Press release.
Its developers plan to investigate additional intermediate dose levels and continue studying the safety and immunological effects of the breast cancer vaccine in two additional patient cohorts.
2023-12-12 22:23:06
#Positive #results #announced #breast #cancer #vaccine #trial
